Serious adverse events · people with active UC
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
It is very uncertain whether probiotics changes withdrawal due to adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes clinical relapse (12 to 52 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes maintenance of clinical remission (52 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events (48 to 52 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
1 finding from 1 review
Need for extra treatment · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life (12 weeks) · Patients with quiescent ulcerative colitis
1 finding from 1 review
Clinical relapse · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in clinical relapse (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Maintenance of clinical remission · Patients with quiescent ulcerative colitis
Probiotics showed no clear difference in maintenance of clinical remission (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
1 finding from 1 review
Serious adverse events (52 weeks) · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review